BPL Medical Technologies brings next-gen Korean ultrasound to India
The X CUBE 50 integrates ALPINION’s advanced X+ Architecture
The X CUBE 50 integrates ALPINION’s advanced X+ Architecture
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
Consolidated revenue from operations stood at Rs. 111.05 crore
Subscribe To Our Newsletter & Stay Updated